On July 10, the U.S. Food and Drug Administration (FDA) approved Otsuka and Lundbeck’s Rexulti (brexpiprazole) for schizophrenia and as an add-on to antidepressants for adults with depression. As the name suggests, it’s chemically and structurally related to aripiprazole (Abilify).
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
This page has links and instructions for downloading your PDF copy of Drug Metabolism in Psychiatry: A Clinical Guide and take the 6 CME Post-Test
James Recht, MD
Psychiatrist based in Cambridge, MA
Dr. Recht has disclosed that he had no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
When we last reviewed neurostimulation devices 3 years ago, we concluded that there was some promise—but more sizzle than beef. Now there are more devices and more data. But is there more beef? Maybe.
Gregory L. Sahlem, MD
Clinical instructor of Psychiatry and Behavioral Sciences, Medical University of South Carolina
Dr. Sahlem has disclosed that the has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.Jeffrey J. Borckardt, PhD
Associate Professor and Director of the Biobehavioral Medicine Division, Brain Stimulation Laboratory and Biobehavioral Medicine Division, Medical University of South Carolina
Dr. Borckhardt has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Carly Simon swears by it. The daytime show “The Doctors” gave it a glowing review. Ads for it seem to be invading psychiatrists’ Google search results. We’re talking, of course, about the Fisher Wallace Stimulator and the similarly touted Alpha-Stim device. How do these devices work? Are they actually effective? And where do they fit into the rapidly expanding array of neuromodulators?
Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
So let’s say you’ve decided to take the TMS plunge. With three devices currently FDA cleared, you have some decisions to make. The following table brings together some information you might find useful focusing on the Neronetics and Brainsway devices.
Mark George, MD
Distinguished University Professor, Layton McCurdy Endowed Chair, Director, Brain Stimulation Laboratory
Dr. George discloses that he is an unpaid consultant to Brainsonix, Brainsway, Cerval/Neostim, Mecta, Neuronetics, NeoSync, Nervive, and Puretech Ventures. Dr. Carlat has reviewed this interview and found no evidence of bias in this educational activity.
Mark George, MD started working on transcranial magnetic stimulation in 1993. In this interview he discusses the history of TMS and the state of trials and treatment options for patients 20 years later.
Nolan Williams, MD
Instructor, Psychiatry and Behavioral Sciences, Stanford University
Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Dr. Williams discusses the field of interventional psychiatry from a practical standpoint by outlining the philosophy, practice, and case studies where interventional strategies have been effective.
Review of this study regarding the effects of a Mediterranean diet on age-related cognitive decline: Valis-Pedret C et al, JAMA Intern Med 2015. 11.doi:10.1001/jamainternmed.2015.1668. Epub ahead of print.